FOI 9457 – Q1

Do you provide autoantibody testing for diagnosis of Type 1 diabetes?

Answer: Yes

Q1a. If yes, please indicate which assays are available either onsite or via referral to another laboratory:

- GAD - Referred
- IA-2 - Referred
- ZnT8 - Referred
- IAA - Referred

Answer:

Q1b. Does your organisation receive requests for Type 1 diabetes autoantibody testing in individuals without clinically diagnosed diabetes (e.g. screening of at-risk relatives or other asymptomatic individuals)?

☐ Yes
☐ No
☑ Unknown

Q1c. Please provide the number of unique patients tested clinically for the following autoantibodies during:

- Calendar year 2025
- January–March 2026 Only this data is available due to LIMS change and generic codes used

Please exclude research-only testing where identifiable. Unable to exclude from data

Please provide separate figures for:

- onsite testing None
- outsourced/referred testing See below

If exact patient numbers are not available, please provide the closest available measure (e.g. request numbers or assay volumes) and specify the metric used. Answer table:

		Patients Tested Onsite	Outside Lab
2025 (Calendar Year)	GAD only	None	Data not readily available
	Combination of any of GAD, IA-2 and/or ZnT8	None	Data not readily available
	IAA only (if available)	None	Unable to collect data as used a generic SAS code
	GAD only	None	None

1st quarter 2026 (January – March)	Combination of any of GAD, IA-2 and/or ZnT8	None	29
	IAA only (if available)	None	Unable to collect data as used a generic SAS code

Q1d. If an external laboratory is used, please provide:

· laboratory/provider name

· location

Answer:

IAA: Sent to SAS Peptides Lab Guildford

GAD: Sent to Royal Devon and Exeter Hospital

IA-2: Sent to Royal Devon and Exeter Hospital

ZnT8: Sent to Royal Devon and Exeter Hospital

Question No. 2	If readily available, please provide the number of unique patients in 2025 and Jan–Mar 2026 who tested positive for: i) one autoantibody ii) two or more autoantibodies Please exclude research-only testing where possible. Answer: Q2b. Of the unique patients who tested positive, how many were referred through an early stage/asymptomatic screening programme? Answer: **Below is the answer to the above question:** (this may be in the form of written text or attachments)

Jan – Mar 2026

1 antibody pos+ = 6

2 or more antibody pos+= 6

(Unable to include IAA in this data)

Question No. 3	Please provide the average turnaround time over the last 12 months for Type 1 diabetes autoantibody testing: • onsite testing • referred testing (if applicable) Answer: **Below is the answer to the above question:** (this may be in the form of written text or attachments)

Average TAT: Referral only 32.3 days – This includes time it takes for us to receive the report and manually enter the results into the LIMS.

Please note that data collected is incomplete due to change in LIMS during the requested date range and the use of a generic send away test code which makes it impossible to gather data for the specific tests requested. Old LIMS data has been archived and is not easily accessible. There will be a gap of data for GAD, IA-2 & ZNT8 data between 15/09/2025 – 15/12/2025 where generic code was used for these tests. No data available for IAA

Data available from Jan 2026